News & Trade Shows

News & Trade shows

Mexico's COFEPRIS Approves Biomerica Test

Mexico's COFEPRIS (Mexico,s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer.

-Biomerica ships first order to Mexico-

Irvine, California -- March 8, 2018 -- Biomerica, Inc. (Nasdaq: BMRA) announced the Mexico's COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios - Mexico's equivalent of the U.S. Food & Drug Administration) approval of the EZ Detect colorectal screening test designed to help identify the early warning signs of colorectal cancer.

Biomerica also announced it has appointed DNA Biopharm (DNA) as its exclusive distributor for its EZ Detect product in Mexico and has shipped the first order of EZ Detect to the company.  DNA has 25 years of expertise in marketing pharmaceutical and medical devices in Latin America.  Oscar H. del Cid, CEO of DNA, stated, "We are excited about the prospects of colorectal cancer screening in Mexico.  The EZ Detect product is unique in that it offers the opportunity of cost savings for the healthcare system while saving lives."

The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. The test does not require handling of stool or dietary restrictions.  The EZ Detect pad is tossed into the toilet after a bowel movement.  A change in the pad's color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool.  The pad is then simply flushed.

Zackary Irani, CEO of Biomerica, stated, "We are excited to work with Oscar and DNA to help enable colorectal screening in Mexico."

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. ( is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.

The Biomerica InFoods IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is available for InFoods diagnostic products. Since the InFoods product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.

Safe Harbor Statement